Evidence map›Paper›PMID 39611661›Full record

SynthesisFuture oncology (London, England)2025

Survival trends using DPd vs. other triplets in early RRMM patients: a population-adjusted indirect treatment comparison.

Faiz Anwer, Tommy Lan, Michael Dolph, Hoora Moradian, Samantha Slaff, Yu-Hsuan Shih, Derek Tang

Erratum issuedAbstract readSystematic ReviewComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Faiz AnwerHematology, Oncology, Multiple Myeloma, Blood and Marrow Transplant Program, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH, USA.
Tommy LanCytel Inc, Cambridge, MA, USA.
Michael DolphCytel Inc, Cambridge, MA, USA.
Hoora MoradianCytel Inc, Cambridge, MA, USA.
Samantha SlaffBristol Myers Squibb, Princeton, NJ, USA.
Yu-Hsuan ShihBristol Myers Squibb, Princeton, NJ, USA.
Derek TangBristol Myers Squibb, Princeton, NJ, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsLimited head-to-head data exist for daratumumab plus pomalidomide and dexamethasone (DPd) and non-pomalidomide-containing triplet regimens to treat relapsed/refractory multiple myeloma (RRMM). This study conducted population-adjusted indirect comparisons of overall survival (OS) for DPd vs. daratumumab, carfilzomib, and dexamethasone (DKd) and daratumumab, bortezomib, and dexamethasone (DVd). MATERIALS &

methodsA systematic literature review was performed via searches of databases and relevant conference proceedings. Both simulated treatment comparison (STC) and matching-adjusted indirect comparison (MAIC) were used to adjust for between-trial differences.

resultsSeven randomized controlled trials were identified, five of which were subsequently excluded from the indirect treatment comparison during feasibility assessment. A consistent OS benefit was observed for DPd vs. DKd and DVd for patients with RRMM, using both STC and MAIC methods.

conclusionsThe findings of this study support the use of DPd over DKd and DVd for the treatment of patients with early RRMM.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsMultiple MyelomaAntibodies, MonoclonalBortezomibDexamethasoneHumansNeoplasm Recurrence, LocalOligopeptidesRandomized Controlled Trials as TopicThalidomideTreatment OutcomeAntibodies, MonoclonalBortezomibcarfilzomibdaratumumabDexamethasoneOligopeptidespomalidomideThalidomideDaratumumab plus pomalidomide and dexamethasonematching-adjusted indirect comparisonmultiple myelomaoverall survivalrelapsed/refractorysimulated treatment comparisontriplet regimens

Identifiers

PMID39611661
PMCPMC11792785

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.